Business
GNCC Capital, Inc. Updates On Its Recently Acquired Colombian Cannabis Company
GNCC Capital, Inc. Updates On Its Recently Acquired Colombian Cannabis Company.
About this update from Gncc Capital, Inc.
[{"type":"text","content":"\n\n\n\nGNCC Capital, Inc. Updates On Its Recently Acquired Colombian Cannabis Company\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGNCC Capital, Inc. Updates On Its Recently Acquired Colombian Cannabis Company\nBioCann Pharma Management introduces their business to GNCC Shareholders\nPR Newswire\nLAS VEGAS, March 18, 2019\n\n\n\nLAS VEGAS, March 18, 2019 /PRNewswire/ -- GNCC Capital, Inc. (OTC: GNCP) (\"The Company\" or \"GNCC\") announced on February 21, 2019 that it had completed the acquisition of BioCann Pharma S.A.S. (\"BioCann\"), a Cannabis CBD Pharmaceutical Grade Oils Producer and Distributor, incorporated in and operating in the Republic of Colombia (\"Colombia\") and with offices in Ontario, Canada.\nFurther to that announcement, we confirm that BioCann has appointed their first Director, Paula Andrea Victoria to the GNCC Board on March 6, 2019, a link to this appointment: https://backend.otcmarkets.com/otcapi/company/financial-report/213059/content.\nThe outgoing Directors of GNCC depart on March 31, 2019, being the close of the \"transition period\". BioCann will be appointing additional Directors to the GNCC Board on or before that date.\nIn the interests of providing complete transparency to investors and to our shareholders, we confirm that GNCC joined the OTC Markets Transfer Agent Verified Shares Program on March 4, 2019, a link to this filing: https://backend.otcmarkets.com/otcapi/company/financial-report/212971/content\nBioCann Management in this communication with shareholders sets out an initial overview of their existing business interests and confirms that BioCann has an equal partnership with Instadose Pharma S.A.S. in Colombia, which is a subsidiary of Canadian based Instadose Pharma Corp. (\"Instadose\"), www.instadosepharma.com. BioCann has sole and exclusive rights with Instadose in Colombia in terms of their partnership agreements. Instadose also has significant and at present, unrelated Cannabis interests in Africa.\nInstadose owns in a Joint Venture, a licensed processing and manufacturing facility which is GMP Certified and complies w...